EMA thumbs up for Clynav vaccine

The Committee for Medicinal Products for Veterinary Use (CVMP) from the
European Medicines Agency (EMA) has recommended the granting of a variation
to the terms of the marketing authorization for Clynav, Elanco´s first in class
DNA vaccine, expanding the duration of its immunity from 3 months to 12
months after vaccination.[1]

Fish vaccinated with Clynav have health benefits such as reduced lesions on
the heart, pancreas and skeletal muscles and reduced risk of death caused
by pancreatic disease following infection with salmonid alphavirus subtype 3

[1] https://www.ema.europa.eu/en/medicines/veterinary/summariesopinion/clynav
[2] https://www.ema.europa.eu/en/medicines/veterinary/EPAR/clynav